Seprafilm

History

2019: Baxter purchased Seprafilm for $350 million

At the beginning of December, 2019 Baxter purchased from Sanofi business on production of the surgical materials Seprafilm for $350 million. The transaction should be closed by the end of the first quarter 2020.

The French company Sanofi reviews the development strategy under the leadership of the new CEO Paul Hudson.

Baxter purchased from Sanofi business on production of the surgical materials Seprafilm for $350 million

Within our current strategic transformation we review our opportunities to focus on the key directions of development — the representative of Sanofi noted.

Though Sanofi aims to expand base of production, having covered not only medicines for treatment of diabetes and cardiovascular diseases, the company is forced to recognize that it faced the cruel competition. In 2018 it spent $11.6 billion for acquisition of the Bioverativ company focused on treatment of hemophilia and $4.8 billion — for purchase of the developer biotechnology of nanobodies of Ablynx.

Seprafilm is engaged in production of the bioresolving barrier used for separation of different tissues of abdominal cavity in the first days after transaction and preventing development of solderings. Spikes can lead to serious complications, such as impassability of a small intestine, and can demand repeated transactions. They appear at 93% of patients after large invasive transactions of an abdominal cavity, and every fifth patient returns for repeated intervention.

Baxter reported that it is going to support a product through own sales department specializing in surgical materials and tools. Seprafilm should become important addition to a portfolio of haemo static and hermetic company funds.^[1]

2011: Sanofi purchased Seprafilm

Sanofi purchased Seprafilm in 2011, and eight years later decided not to make additional resources and to transfer business of other company.